Targets › OXTR
8 programs from 7 companies in 17 trials: 12 Phase 2, 3 Phase 4, 1 Phase 1, 1 Phase 3; Metabolic and endocrine, Other, Psychiatry; next expected readout Dec 2026.
G protein-coupled receptor for oxytocin (OXT), a neuropeptide hormone released by the posterior pituitary gland that plays a key role in social behavior and other biological processes, such as milk ejection. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as phospholipase C. OXTR is…. (UniProt, P30559)
Open in Phaseline: the race on OXTR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Yale University | Oxytocin Oxytocin receptor agonist | OXTR | Phase 4 | Oxytocin; Pain | Nov 2028 |
| ACADIA Pharmaceuticals | Carbetocin (ACP-101) Oxytocin receptor agonist | OXTR | Phase 3 | Hyperphagia in Prader-Willi Syndrome; Postpartum Hemorrhage | – |
| University Hospital, Basel, Switzerland | Oxytocin Oxytocin receptor agonist | OXTR | Phase 2 | Arginine Vasopressin Deficiency | Dec 2026 |
| Massachusetts General Hospital | Oxytocin Oxytocin receptor agonist | OXTR | Phase 2 | Binge-eating Disorder; Obesity, Adolescent | Dec 2026 |
| Elizabeth Austen Lawson | Oxytocin Oxytocin receptor agonist | OXTR | Phase 2 | Autism Spectrum Disorder; Vasopressin Deficiency | Jun 2027 |
| University of Nebraska | Oxytocin Oxytocin receptor agonist | OXTR | Phase 2 | Stress | Nov 2027 |
| University Hospital, Basel, Switzerland | Intranasal OXT (Syntocinon®) Oxytocin receptor agonist | OXTR | Phase 2 | Central Diabetes Insipidus (cDI) | – |
| Memorial University of Newfoundland | Oxytocin Oxytocin receptor agonist | OXTR | Phase 2 | Chronic Pain | – |
Pain (2) Arginine Vasopressin Deficiency (2) Chronic Pain (2) Stress (2) Postpartum Hemorrhage (2) Oxytocin (1) Autism Spectrum Disorder (1) Vasopressin Deficiency (1) Central Diabetes Insipidus (cDI) (1) Binge-eating Disorder (1) Obesity, Adolescent (1) Hyperphagia in Prader-Willi Syndrome (1)
small molecule (8)
University Hospital, Basel, Switzerland (2) Yale University (1) Elizabeth Austen Lawson (1) Massachusetts General Hospital (1) Memorial University of Newfoundland (1) University of Nebraska (1) ACADIA Pharmaceuticals (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.